Connect every life science node to AI intelligence that powers your decisions
Discover the scientific risk behind any deal, mapped in hours, not weeks — every claim traced to its source, every gap surfaced before the investment committee.
Programs & affiliations
We support the licensing, M&A and investment decision makers in life science sector. The AI-powered diligence is disease area agnostic and can support evaluation of assets from public and private companies.
Biotech
01Companies and founders evaluating assets, partners, and the competitive landscape around them.
Pharma
02Business development and BD teams evaluating in-licensing, partnerships, and acquisitions.
Life science investors
03VC, crossover, and growth funds running diligence on biotech deals at speed, with conviction.
Advisors & analysts
04Deal advisors and analysts who run diligence for clients and need insights they can trust.
Agentic AI that maps the scientific risk
Agents find every relevant source, bind each claim to it, and cross-check the full external record — then hand you the risk map behind the technology.
Ingest
The full data room — pitch decks, study reports, patents, CMC records, regulatory filings and market research — is ingested. Gap assessments and missing information are identified.
Index
Every assertion becomes a connected claim, bound to its exact source. Every diligence builds the proprietary knowledge graph.
Intelligence layer
Agents test each claim against the external record for gaps and risks. Real-world results bound to references are prioritized for trusted analysis.
Scientific risk map
A defensible view of the technology, delivered in the review platform — group review and evidence sharing inside the deal team.
A live report from your intelligence layer
A live slice of the workspace — ask a question, get a receipt.
Conditional
Source confidence
62
Uploaded files
Revonode report
Does the Phase 2 data support the efficacy claim in the deck?
Revonode
Partly. The deck claims a 68% responder rate; the study report gives 68% for the 100 µg arm only, n=23, with no active comparator. The pooled figure across all arms is 54%. Two of the three cited supporting papers sit behind programmes that failed in humans — down-weighted, not hidden.
Illustrative dataset — the interface is live, the deal is invented.
More capacity, and more confidence in every call
2% → the whole funnel
Today, 2% of what you screen reaches a deep review — each one costing a five-domain specialist team on the order of 50 hours. The rest are dropped for want of bandwidth, not merit.
- not gated on specialist availability
- the whole funnel, not the top of it
- seven dimensions on every deal
Every claim bound
Every answer is traced to the page it came from — not to a plausible-sounding summary.
- outcome-graded, not citation-ranked
- gaps stated, never inferred
- one standardized score across the funnel
One risk oversight can cost hundreds of millions
After months of diligence we licensed a rare-disease drug ready for phase III. The team missed one document, a competitor's orphan-drug designation, and lost market access to seven years of exclusivity.
Top-20 pharma director, global business development
The things investors and partners ask us most.
Every claim binds to its exact source, and agents independently cross-check it against the external record across literature, clinical, regulatory, IP, and market. You can land on the sentence on the page in seconds, and if it can't show its receipt, it isn't asserted.
Gaps, the claims the deal's own evidence can't support, and risks: contradicting literature, failed or crowded trials, and competing patents. You see the landmines before the IC meeting, not after.
Your confidential and sensitive data is protected in our isolated data sets. Your data stays under your license so no co-investor, competing investor or analyst can access your information.
No. Company private reasoning layer is isolated by architecture. Only public knowledge is shared between reports while your confidential content and conclusions never leave your license.
You can start by contacting us for an introduction call or alternatively, bring us a deal you need assessed. We index the provided data, cross-check it against the external record, and provide you the diligence, and the gaps and risks, in hours.
Two things drive it: a license sized by how much deal material you keep indexed with us, and investigation tokens consumed by the deals you actually put through diligence. There are no seat counts and no per-document fees. Tell us your deal volume and we will quote it.
No. The interface is the real product, the deal is invented. Every company, figure and document in the walkthrough is fictional, because publishing a risk verdict about a real company would be neither fair nor accurate.
Bring us a deal.
See the diligence in hours.
Hand us a live or past data room. We'll index it, cross-check it against the external record, and show you the gaps and risks.